Therapeutic innovations in triple negative breast cancer: integrating molecular targeting and monoclonal antibody strategies
{{output}}
Triple Negative Breast Cancer (TNBC) is a specific kind of breast cancer that is distinguished by the lack of expression of three specific receptors, namely human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), and progesterone receptor (PR)... ...
